A detailed history of Mitchell Capital Management CO transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Mitchell Capital Management CO holds 15,453 shares of VRTX stock, worth $7.18 Million. This represents 1.31% of its overall portfolio holdings.

Number of Shares
15,453
Previous 15,968 3.23%
Holding current value
$7.18 Million
Previous $7.48 Million 3.98%
% of portfolio
1.31%
Previous 1.37%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$460.0 - $505.78 $236,900 - $260,476
-515 Reduced 3.23%
15,453 $7.19 Million
Q2 2024

Aug 08, 2024

BUY
$392.81 - $485.53 $106,451 - $131,578
271 Added 1.73%
15,968 $7.48 Million
Q1 2024

May 06, 2024

BUY
$407.69 - $446.08 $1.67 Million - $1.82 Million
4,086 Added 35.19%
15,697 $6.56 Million
Q4 2023

Feb 13, 2024

BUY
$343.0 - $410.68 $18,179 - $21,766
53 Added 0.46%
11,611 $4.72 Million
Q3 2023

Nov 03, 2023

SELL
$338.18 - $362.46 $11,159 - $11,961
-33 Reduced 0.28%
11,558 $4.02 Million
Q2 2023

Aug 08, 2023

SELL
$314.42 - $351.91 $105,016 - $117,537
-334 Reduced 2.8%
11,591 $4.08 Million
Q1 2023

May 08, 2023

BUY
$283.23 - $323.1 $7,930 - $9,046
28 Added 0.24%
11,925 $3.76 Million
Q4 2022

Feb 13, 2023

SELL
$285.76 - $321.48 $6,286 - $7,072
-22 Reduced 0.18%
11,897 $3.44 Million
Q3 2022

Oct 28, 2022

BUY
$273.83 - $305.53 $25,466 - $28,414
93 Added 0.79%
11,919 $3.45 Million
Q2 2022

Jul 29, 2022

BUY
$234.96 - $292.55 $2.78 Million - $3.46 Million
11,826 New
11,826 $3.33 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Mitchell Capital Management CO Portfolio

Follow Mitchell Capital Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitchell Capital Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Mitchell Capital Management CO with notifications on news.